Letter regarding trademark use and acquisition between Medicis and Inamed, and agreement for Q-Med to forgo non-competition clauses under 'Restylane' and 'Sub-Q' patent agreements until a comprehensive agreement is reached, with royalty due if comprehensive agreement is not executed within 6 months on Inamed products, including Hylaform, Zyplast, and Zyderm.
- DOI
- 10.34675/l14829
- Published
- 2005
- Container
- Not recorded
- Publisher
- RoyaltyStat
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.34675/l14829,
title = {Letter regarding trademark use and acquisition between Medicis and Inamed, and agreement for Q-Med to forgo non-competition clauses under 'Restylane' and 'Sub-Q' patent agreements until a comprehensive agreement is reached, with royalty due if comprehensive agreement is not executed within 6 months on Inamed products, including Hylaform, Zyplast, and Zyderm.},
author = {RoyaltyStat},
year = {2005},
doi = {10.34675/l14829},
url = {https://doi.org/10.34675/l14829}
}RIS
TY - JOUR TI - Letter regarding trademark use and acquisition between Medicis and Inamed, and agreement for Q-Med to forgo non-competition clauses under 'Restylane' and 'Sub-Q' patent agreements until a comprehensive agreement is reached, with royalty due if comprehensive agreement is not executed within 6 months on Inamed products, including Hylaform, Zyplast, and Zyderm. AU - RoyaltyStat PY - 2005 DO - 10.34675/l14829 UR - https://doi.org/10.34675/l14829 ER -
APA
RoyaltyStat (2005). Letter regarding trademark use and acquisition between Medicis and Inamed, and agreement for Q-Med to forgo non-competition clauses under 'Restylane' and 'Sub-Q' patent agreements until a comprehensive agreement is reached, with royalty due if comprehensive agreement is not executed within 6 months on Inamed products, including Hylaform, Zyplast, and Zyderm.. https://doi.org/10.34675/l14829
Source records
- datacite · retrieved 2026-09-26T01:11:18.346Z